Tekmira Pharmaceuticals Corp  

(Public, NASDAQ:TKMR)   Watch this stock  
Find more results for TKMR
-0.25 (-1.32%)
Apr 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 18.61 - 19.60
52 week 8.86 - 29.93
Open 19.11
Vol / Avg. 404,084.00/848,074.00
Mkt cap 873.14M
P/E     -
Div/yield     -
EPS -1.71
Shares 46.57M
Beta 0.34
Inst. own 19%
May 7, 2015
Tekmira Pharmaceuticals Corp at Deutsche Bank Health Care Conference - 11:20AM EDT - Add to calendar
May 6, 2015
Q1 2015 Tekmira Pharmaceuticals Corp Earnings Call - 4:30PM EDT - Add to calendar
May 6, 2015
Q1 2015 Tekmira Pharmaceuticals Corp Earnings Release - 4:00PM EDT - Add to calendar
Mar 12, 2015
Q4 2014 Tekmira Pharmaceuticals Corp Earnings Call - Webcast
Mar 12, 2015
Q4 2014 Tekmira Pharmaceuticals Corp Earnings Release
Mar 11, 2015
Tekmira Pharmaceuticals Corp at Barclays Healthcare Conference - Webcast
Mar 3, 2015
Tekmira Pharmaceuticals Corp Extraordinary Shareholders Meeting
Feb 24, 2015
Tekmira Pharmaceuticals Corp at RBC Healthcare Conference
Feb 12, 2015
Tekmira Pharmaceuticals Corp at Leerink Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -197.25% -90.95%
Operating margin -156.90% -78.59%
EBITD margin - -74.63%
Return on average assets -26.84% -22.63%
Return on average equity -34.40% -28.10%
Employees 85 -
CDP Score - -


100-8900 Glenlyon Pky
+1-604-4193200 (Phone)
+1-604-4193201 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (RNA) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical and biotechnology partners. Its product candidates include TKM-HBV, TKM-PLK1, TKM-Ebola and TKM-Marburg. TKM-HBV is an RNAi therapeutic for the treatment of Hepatitis B infection. The Company�s lead oncology product candidate, TKM -PLK1 is an oncology product platform that targets polo-like kinase 1 (PLK1), a protein involved in tumor cell proliferation and a validated oncology target. TKM-ALDH2 is an application of RNAi for alcohol use disorder with a target patient population who have moderate to severe alcohol use disorder. TKM-Ebola is an anti-Ebola viral therapeutic being developed under a contract with the United States Department of Defense Joint Project Manager Medical Countermeasure Systems. TKM-Marburg is used to treat hemorrhagic fever viral infections.

Officers and directors

Vivek Ramaswamy Chairman of the Board
Bio & Compensation  - Reuters
Mark J. Murray Ph.D. President, Chief Executive Officer, Director
Age: 65
Bio & Compensation  - Reuters
Bruce G. Cousins Chief Financial Officer, Executive Vice President
Age: 53
Bio & Compensation  - Reuters
Michael J. Abrams Ph.D. Executive Vice President and Chief Discovery Officer
Age: 57
Bio & Compensation  - Reuters
Adam D. Cutler Senior Vice President - Corporate Affairs
Bio & Compensation  - Reuters
Mark Kowalski M.D., Ph.D. Chief Medical Officer, Senior Vice President
Age: 59
Bio & Compensation  - Reuters
Peter Lutwyche Ph.D. Senior Vice President - Pharmaceutical Development
Bio & Compensation  - Reuters
Bruce Dorsey Vice President - Chemistry
Bio & Compensation  - Reuters
Rene Cornelis Rijnbrand Vice President - Biology
Bio & Compensation  - Reuters
R. Hector MacKay-Dunn Q.C. Corporate Secretary
Age: 62
Bio & Compensation  - Reuters